T1	Participants 352 476	patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy
T2	Participants 478 689	Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab
T3	Participants 868 965	1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy
